BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 562781)

  • 1. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI; Das RP; Madoiya KK; Jain AK; Roy S
    Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
    Niaraki MA; Moghissi KS; Borin K
    Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C; Yeung KK
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women.
    Hirvonen E; Stenman UH; Mälkönen M; Rasi V; Vartiainen E; Ylöstalo P
    Maturitas; 1988 Oct; 10(3):201-13. PubMed ID: 2972897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to intermittent RU486 in women.
    Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
    Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary-ovarian function after tubal ligation.
    Alvarez-Sanchez F; Segal SJ; Brache V; Adejuwon CA; Leon P; Faundes A
    Fertil Steril; 1981 Nov; 36(5):606-9. PubMed ID: 7308505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
    Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J
    Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal relationship between Uniplant insertion and changes in cervical mucus.
    Barbosa IC; Coutinho E; Hirsch C; Ladipo OA; Olsson SE; Ulmsten U
    Contraception; 1996 Oct; 54(4):213-7. PubMed ID: 8922874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.